Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Пароксизмальная ночная гемоглобинурия

Список литературы

  1. Bessler M. et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. // EMBO J. 1994. Vol. 13, № 1. P. 110–117.
  2. Takeda J. et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria // Cell. 1993. Vol. 73, № 4. P. 703–711.
  3. Medof B.Y.M.E., Kinoshita T., Nussenzweig V. INHIBITION OF COMPLEMENT OF CELLS AFTER ACTIVATION ON THE OF INCORPORATION ( DAF ) INTO THEIR MEMBRANES A key step in complement activation on targets is the deposition of C4b and / or C3b fragments . These major cleavage products of C3 and C4 can associa // Journal of Experimental Medicine. 1984. Vol. 160, № November. P. 1558–1578.
  4. Lublin D.M., Atkinson J.P. Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function // Annu Rev Immunol. 1989. Vol. 7, № 1. P. 35–58.
  5. Rollins S.A., Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. // The Journal of Immunology. 1990. Vol. 144, № 9. P. 3478 LP – 3483.
  6. Noris M., Remuzzi G. Overview of complement activation and regulation // Semin Nephrol. Elsevier, 2013. Vol. 33, № 6. P. 479–492.
  7. Tegla C.A. et al. Membrane attack by complement: the assembly and biology of terminal complement complexes // Immunol Res. 2011. Vol. 51, № 1. P. 45–60.
  8. Serna M. et al. Structural basis of complement membrane attack complex formation // Nat Commun. Nature Publishing Group, 2016. Vol. 7. P. 1–7.
  9. Sun X. et al. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting // Proc Natl Acad Sci U S A. 1999. Vol. 96, № 2. P. 628–633.
  10. Brodbeck W.G. et al. Structure/function studies of human decay-accelerating factor // Immunology. 2000. Vol. 101, № 1. P. 104–111.
  11. Farkas I. et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9 // J Physiol. 2002. Vol. 539, № 2. P. 537–545.
  12. Bessler M., Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria. // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2008. P. 104–110.
  13. Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria // Blood. 2013. Vol. 121, № 25. P. 4985–4996.
  14. Rother R.P. et al. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin // JAMA. 2005. Vol. 293, № 13. P. 1653.
  15. Olsen S.B. et al. Enhancement of Platelet Deposition by Cross-Linked Hemoglobin in a Rat Carotid Endarterectomy Model // Circulation. 1996. Vol. 93, № 2. P. 327–332.
  16. Simionatto C.S. et al. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers // Am J Med. 1988. Vol. 85, № 4. P. 538–540.
  17. Studt J.-D. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin // Blood. 2005. Vol. 105, № 2. P. 542–544.
  18. Seregina E.A. et al. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria // Blood Cells Mol Dis. 2015. Vol. 54, № 2. P. 144–150.
  19. Ritis K. et al. A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways // The Journal of Immunology. 2006. Vol. 177, № 7. P. 4794–4802.
  20. Wojta J. et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils // Blood. 2002. Vol. 100, № 2. P. 517–523.
  21. Yu F., Du Y., Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America // Int J Hematol. Springer Japan, 2016. Vol. 103, № 6. P. 649–654.
  22. Hill A. et al. Paroxysmal nocturnal haemoglobinuria // Nat Rev Dis Primers. 2017. Vol. 3, № 1. P. 17028.
  23. Hill A. et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. // Blood. 2006. Vol. 108, № September 2018. P. Abstract 985.
  24. Кулагин А.Д. et al. Клиническая манифестация и ошибки диагностики классической пароксизмальной ночной гемоглобинурии : анализ 150 наблюдений // Клиническая онкогематология. 2017. Vol. 10, № 3. P. 333–341.
  25. Hillmen P. et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria // Am J Hematol. 2010. Vol. 85, № 8. P. 553–559.
  26. Hill A. et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: Raised pulmonary pressure and reduced right ventricular function // Br J Haematol. 2012. Vol. 158, № 3. P. 409–414.
  27. Sahin F. et al. Pesg PNH diagnosis , follow-up and treatment guidelines. 2016. Vol. 6, № 2. P. 19–27.
  28. Brodsky R.A. Paroxysmal nocturnal hemoglobinuria // Blood. 2014. Vol. 124, № 18. P. 2804–2811.
  29. Кулагин А.Д. et al. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии // Онкогематология. 2014. Vol. 2. P. 20–28.
  30. Borowitz M.J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry // Cytometry B Clin Cytom. Wiley-Liss Inc., 2010. Vol. 78, № 4. P. 211–230.
  31. Manivannan P., Ahuja A., Pati H.P. Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances // Indian Journal of Hematology and Blood Transfusion. Springer India, 2017. Vol. 33, № 4. P. 453–462.
  32. Movalia M.K. et al. Incidence of PNH Clones by Diagnostic Code Utilizing High Sensitivity Flow Cytometry // Blood. 2011. Vol. 118, № 21. P. 1033–1033.
  33. Sipol A.A. et al. An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort // Hematology. 2015. Vol. 20, № 1. P. 31–38.
  34. Dezern A.E., Borowitz M.J. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 – clinical utility // Cytometry B Clin Cytom. 2018. Vol. 94, № 1. P. 16–22.
  35. Sutherland D.R. et al. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 – reagent selection and assay optimization for high-sensitivity testing // Cytometry B Clin Cytom. 2018. Vol. 94, № 1. P. 23–48.
  36. Brubaker L.H., Essig L.R.J., Mengel C.E. Neutrophil life span in paroxysmal nocturnal hemoglobinuria // Blood. 1977. Vol. 50, № 4. P. 657–662.
  37. Patriquin C.J. et al. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry // European Journal of Haematology. Blackwell Publishing Ltd, 2019. Vol. 102, № 1. P. 36–52.
  38. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). // Флебология. 2015. Vol. 4, № 2. P. 3–52.
  39. Villegas A. et al. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria // Med Clin (Barc). Ediciones Doyma, S.L., 2016. Vol. 146, № 6. P. 278e1-278e7.
  40. Hill A. et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria // Blood. 2005. Vol. 106, № 7. P. 2559–2565.
  41. Hillmen P. et al. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria // New England Journal of Medicine. 2006. Vol. 355, № 12. P. 1233–1243.
  42. Savva S. The Potential of a Museum-School Partnership to Support Diversity and Multiliteracies-Based Pedagogy for the 21st Century. 2016. Vol. 111, № 4. P. 1840–1848.
  43. Hillmen P. et al. Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria // New England Journal of Medicine. 2004. Vol. 350, № 6. P. 552–559.
  44. Reiss U.M. et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria // Pediatr Blood Cancer. Pediatr Blood Cancer, 2014. Vol. 61, № 9. P. 1544–1550.
  45. Lee J.W. et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study // Blood. 2019. Vol. 133, № 6. P. 530–539.
  46. Kulasekararaj A.G. et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study // Blood. 2019. Vol. 133, № 6. P. 540–549.
  47. McNamara L.A. et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine // MMWR Morb Mortal Wkly Rep. 2017. Vol. 66, № 27. P. 734–737.
  48. Brodsky R.A. et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria // Haematologica. 2020. Vol. 106, № 1. P. 230–237.
  49. Инструкция по медицинскому применению препарата пэгцетакоплан ЛП-№(002459)-(РГ-RU) от 02.06.2023. Государственный реестр лекарственных средств.
  50. Debureaux P.-E. et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study // Bone Marrow Transplant. 2021. Vol. 56, № 10. P. 2600–2602.
  51. Brodsky R.A. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. 2010. Vol. 95, № 6. P. 855–856.
  52. de Latour R.P. et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria // Haematologica. 2012. Vol. 97, № 11. P. 1666–1673.
  53. SHASHELEVA D.A. et al. Hematopoietic stem cell transplantation with alpha/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria // Ter Arkh. 2018. Vol. 90, № 7. P. 57–64.
  54. Young N.S. et al. The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients // Semin Hematol. W.B. Saunders, 2009. Vol. 46, № SUPPL. 1.
  55. Brecher M., Taswell H. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited // Transfusion (Paris). 1989. Vol. 29, № 8. P. 681–685.
  56. Parker C. Diagnosis and management of paroxysmal nocturnal hemoglobinuria // Blood. 2005. Vol. 106, № 12. P. 3699–3709.
  57. Cançado R.D. et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria // Hematol Transfus Cell Ther. 2021. Vol. 43, № 3. P. 341–348.
  58. Kulasekararaj A.G., Brodsky R.A., Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor // Am J Hematol. 2021. Vol. 96, № 7.
  59. Ayuk F., Balduzzi A. Donor Selection for Adults and Pediatrics // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies / ed. Carreras E. et al. Springer, 2019. P. 87–99.
  60. Carreras E., Rambaldi A. Evaluation and Counseling of Candidates // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 77–87.
  61. Confer D.L., Miller J.P., Chell J.W. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 1–2. P. 423–432.
  62. Witt V., Peters C. Collection of HSC in Children // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 123–127.
  63. Gorin N.C. Bone Marrow Harvesting for HSCT // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 109–117.
  64. Gorin N.C. Bone Marrow Harvesting for HSCT // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 109–117.
  65. Hübel K. Mobilization and Collection of HSC // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 117–123.
  66. Querol S., Rocha V. Procurement and Management of Cord Blood // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 131–137.
  67. Wuchter P. Processing, Cryopreserving and Controlling the Quality of HSCs // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 127–131.
  68. Schumm M., Lang P., Handgretinger R. Graft Manipulation // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 137–143.
  69. Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99–109.
  70. Danylesko I., Shimoni A., Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike // Bone Marrow Transplantation 2012 47:1. Nature Publishing Group, 2011. Vol. 47, № 1. P. 5–14.
  71. Ruutu T. How to use busulfan in conditioning for allogeneic transplantation // Cell Ther Transplant. Universitatsklinikum Hamburg - Eppendorf, 2018. Vol. 7, № 1. P. 18–20.
  72. Langenhorst J.B. et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation // Clin Pharmacokinet. Springer, 2019. Vol. 58, № 5. P. 627.
  73. Yoshida N. et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide // Bone Marrow Transplantation 2020 55:7. Nature Publishing Group, 2020. Vol. 55, № 7. P. 1272–1281.
  74. Penack O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 2. P. e157–e167.
  75. Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
  76. Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
  77. Watanabe N. et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children // Bone Marrow Transplantation 2010 45:7. Nature Publishing Group, 2009. Vol. 45, № 7. P. 1161–1166.
  78. Jacoby E. et al. Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies // Biol Blood Marrow Transplant. NIH Public Access, 2016. Vol. 22, № 1. P. 112.
  79. Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation // Haematologica. 2017. Vol. 102, № 2.
  80. Koreth J. et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, № 3. P. 522–530.
  81. Wertheimer T. et al. Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis // Ann Hematol. 2021. Vol. 100, № 3. P. 779–787.
  82. Drobyski W.R. et al. Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease // Biology of Blood and Marrow Transplantation. Elsevier, 2011. Vol. 17, № 12. P. 1862–1868.
  83. Abouelnasr A. et al. Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment // Biology of Blood and Marrow Transplantation. 2013. Vol. 19. P. 12–21.
  84. Schäfer H. et al. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT // Annals of Hematology 2021 100:8. Springer, 2021. Vol. 100, № 8. P. 2095–2103.
  85. Malard F. et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study // Blood. Content Repository Only!, 2017. Vol. 130, № 20. P. 2186–2195.
  86. Cutler C., Antin J.H. Manifestations and Treatment of Acute Graft-versus-Host Disease // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 2–2. P. 1012–1025.
  87. Holler E., Greinix H., Zeiser R. Acute Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 323–330.
  88. Toubai T., Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 136, № 4. P. 429–440.
  89. Martin P.J. How I treat steroid-refractory acute graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 135, № 19. P. 1630–1638.
  90. Nassar A. et al. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation // J Transplant. Hindawi Limited, 2014. Vol. 2014. P. 1–10.
  91. Kawashima N. et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan // International Journal of Hematology 2019 109:4. Springer, 2019. Vol. 109, № 4. P. 491–498.
  92. Khandelwal P. et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients // Pediatr Transplant. Pediatr Transplant, 2014. Vol. 18, № 1. P. 94–102.
  93. Vicent M.G. et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results // Am J Hematol. John Wiley & Sons, Ltd, 2019. Vol. 94, № 3. P. 319–326.
  94. Faraci M. et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients // Biology of Blood and Marrow Transplantation. Elsevier, 2019. Vol. 25, № 4. P. 743–748.
  95. Sleight B.S. et al. Infliximab for GVHD therapy in children // Bone Marrow Transplantation 2007 40:5. Nature Publishing Group, 2007. Vol. 40, № 5. P. 473–480.
  96. Albert M.H. et al. Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment // Pediatr Transplant. Pediatr Transplant, 2007. Vol. 11, № 3. P. 306–309.
  97. Zangrilli A. et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus // Pediatrics International. Pediatr Int, 2010. Vol. 52, № 3. P. e161-3.
  98. Baird K. et al. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease // Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2015. Vol. 21, № 6. P. 1083–1090.
  99. Wolff D., Lawitschka A. Chronic Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 331–347.
  100. Filipovich A.H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report // Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2005. Vol. 11, № 12. P. 945–956.
  101. Jagasia M.H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report // Biology of Blood and Marrow Transplantation. Elsevier Inc., 2015. Vol. 21, № 3. P. 389-401.e1.
  102. Mikulska M. Infection Control and Isolation Procedures // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 189–197.
  103. Mikulska M. Neutropenic Fever // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 259–265.
  104. Ljungman P., Styczynski J., Einsele H. Viral Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 281–291.
  105. Maertens J.A. Invasive Fungal Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 273–281.
  106. Groll A.H. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation // The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, № 8.
  107. Cesaro S. Haemorrhagic Cystitis and Renal Dysfunction // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 387–393.
  108. Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 315–323.
  109. Mahadeo K.M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 1. P. e61–e72.
  110. Sung L. et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation // BMJ Supportive and Palliative Care. BMJ Publishing Group, 2017. Vol. 7, № 1. P. 7–16.
  111. Ghali M.G.Z. et al. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management // Leukemia and Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, № 10. P. 2365–2372.
  112. Cooke K.R. Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again // Pediatr Transplant. John Wiley & Sons, Ltd, 2005. Vol. 9, № SUPPL. 7. P. 25–36.
  113. Jodele S. et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy // Transfusion and Apheresis Science. Elsevier Ltd, 2016. Vol. 54, № 2. P. 181–190.
  114. Baumgartner A., Schuetz P. Nutritional Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 171–177.
  115. Schrezenmeier H. et al. Transfusion Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 163–171.
  116. Bahar B., Tormey C.A. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future // Archives of Pathology and Laboratory Medicine. College of American Pathologists, 2018. Vol. 142, № 5. P. 662–667.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*